Menu
Not yet recruiting NCT07535242

Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

— Observational Multiple Sclerosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Multiple Sclerosis. Basic parameters: 18 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis

Overview

This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.

Primary outcome measures

  • Expanded Disability Status Scale (EDSS) [Time frame: Baseline]
  • Standardized Mini-Mental Test [Time frame: Baseline]
  • Symbol Digit Modalities Test [Time frame: Baseline]
  • Multiple Sclerosis Impact Scale (MSIS-29) [Time frame: Baseline]
  • Glial Fibrillary Acidic Protein (GFAP) [Time frame: Baseline]
  • Neurofilament Light Chain (NfL) [Time frame: Baseline]
  • Vascular Endothelial Growth Factor (VEGF) [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Confirmed diagnosis of MS
  • Progressive type MS
  • Voluntary participation
  • Age between 18-60 years
  • Cooperative
  • EDSS score ≥ 5.5

Exclusion criteria

  • Presence of another neurological disorder
  • Change in medication within the last 3 months
  • Relapse within the last 3 months

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07535242 · 2025/426

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗